AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06426797
Drug: Cadonilimab plus anlotinib
RxNorm normalized name: Cadonilimab
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cadonilimab (10mg/Kg, ivgtt, d1) and anlotinib (12mg, P.O., d1-d14) on a 21-day regimen for 3 cycles
Trial: NCT04955938
Drug: Ivosidenib
RxNorm normalized name: ivosidenib
DrugBank: Ivosidenib (DB14568)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A drug used to treat acute myeloid leukemia that has a mutated (changed) form of a gene called isocitrate dehydrogenase-1 (IDH1).
Trial: NCT04955938
Drug: Enasidenib
RxNorm normalized name: Enasidenib
DrugBank: Enasidenib (DB13874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A drug used to treat acute myeloid leukemia (AML) that has recurred (come back) or has not gotten better after treatment with other anticancer therapy.
Trial: NCT04955938
Drug: Fedratinib
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This medication is used to treat a certain type of cancer (myelofibrosis). Fedratinib belongs to a class of drugs known as JAK (janus kinase) inhibitors. It works by slowing or stopping the growth of cancer cells.
Trial: NCT05914467
Drug: Teicoplanin
RxNorm normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose will be adjusted in the study arm using MIPD guided TDM- dosing
Trial: NCT06571461
Drug: Liposomal Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Liposomal Irinotecan：i.v. infusion
Trial: NCT06571461
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin;：i.v. infusion
Trial: NCT06571461
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1: Oral
Trial: NCT06571461
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine: i.v. infusion
Trial: NCT05464628
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
Trial: NCT05464628
Drug: ASC42
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Atorvastatin followed by ASC42 daily followed by separate co-administration of atorvastatin
Trial: NCT05305313
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
Trial: NCT05458193
Drug: Daridorexant
RxNorm normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Film-coated tablet for oral use
Trial: NCT04851535
Drug: Jaktinib Hydrochloride Tablets
RxNorm normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jaktinib 100mg Bid
Trial: NCT04720534
Drug: ARO-APOC3
RxNorm normalized name: ARO-APOC3
DrugBank: ARO-APOC3 (DB17625)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of ARO-APOC3 by subcutaneous (sc) injection
Trial: NCT05061446
Drug: Etrasimod
RxNorm normalized name: Etrasimod
DrugBank: Etrasimod (DB14766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etrasimod tablet by mouth, once daily for 12 weeks
Trial: NCT05995444
Drug: Epetraborole and matching placebo
DrugBank: Epetraborole (DB11744)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment A (Therapeutic): 500 mg epetraborole (2 x 250 mg tablets) and epetraborole matching-placebo (6 tablets)
Trial: NCT00002010
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05211622
Drug: 3. chlorhexidine 0,2% - mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 minute- three times/die after oral hygiene, possibly, from five days after the beginning of chemotherapy and for subsequent 2 weeks
Trial: NCT05211622
Drug: 4. sodium bicarbonate 5% solution - mouthwash
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 minute- three times/die after oral hygiene, possibly, from the beginning of chemotherapy and for 3 weeks
Trial: NCT05383170
Drug: Pembrolizumab 25 MG/ML [KEYTRUDA®]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT04705077
Drug: SR419
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 formulations of SR419, SR419 suspension and SR419 capsule will be used in the study.
Trial: NCT05795933
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of intramuscular 200,000 IU vitamin D3 within 24 hours of admission
Trial: NCT05995444
Drug: Epetraborole
RxNorm normalized name: Epetraborole
DrugBank: Epetraborole (DB11744)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment B (Supratherapeutic): 2000 mg epetraborole (8 x 250 mg tablets)
Trial: NCT05995444
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment D (Positive control): 400 mg moxifloxacin (1 x 400 mg tablet)
Trial: NCT06349044
Drug: Anti-PD-1 monoclonal antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200mg d1 iv q3w
Trial: NCT06349044
Drug: Gemcitabine and Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine1000mg/m2 d1 d8 iv；Cisplatin 25mg/m2 d1 d8 iv q3w
Trial: NCT06430372
Drug: Bev-ICG
RxNorm normalized name: ICG-136
DrugBank: ICG-136 (DB17343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probe targeting VEGF-A that is topically administrated during the endoscopy
Trial: NCT05559619
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg of natural calcium carbonate once daily for 12 weeks
Trial: NCT05559619
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU vitamin D3 once daily for 12 weeks
Trial: NCT06321705
Drug: CS1
RxNorm normalized name: CAR BCMA-CS1
DrugBank: CAR BCMA-CS1 (DB17313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CS1 delayed release capsules will be supplied with 160 mg active pharmaceutical ingredient (API) per capsule. Three dose levels will be administered in this expanded access study at the same dose the patient received in the parent study (CS1-003) of 480 mg, 960 mg, or 1920 mg. All patients will later have the option to be titrated to the most efficacious and safe dose determined from the ongoing CS1-003 study when completed.
Trial: NCT05486949
Drug: AZD4205 and carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with carbamazepine after the wash-out period.
Trial: NCT05486949
Drug: AZD4205 and itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with itraconazole after the wash-out period.
Trial: NCT06463535
Drug: Omega 3
RxNorm normalized name: omega 3,6
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + OMEGA 3
Trial: NCT04819360
Drug: VESIcare 10Mg Tablet
RxNorm normalized name: VESIcare 10mg Tablet
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vesicare® 10 mg per day for 12 weeks~Vesicare 10mg 12 weeks
Trial: NCT04609319
Drug: Dacomitinib
RxNorm normalized name: DACOMITINIB
DrugBank: Dacomitinib (DB11963)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is a non-interventional, real world study of Asian patients being treated with dacomitinib as first-line treatment for EGFR+ NSCLC
Trial: NCT05154903
Drug: Citicoline 500 MG
RxNorm normalized name: citicoline 500 MG
DrugBank: Citicoline (DB12153)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citicoline will be administered in continuous iv infusion in a dose of 2000 mg per day for the first week following AIS then by oral route for the next 5 weeks.
Trial: NCT05443984
Drug: Esomeprazole 40mg
RxNorm normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)
Trial: NCT05776108
Drug: Cabotegravir IR Formulation (reference)
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabotegravir IR Formulation (reference) will be administered.
Trial: NCT05776108
Drug: Cabotegravir DT Formulation (test 1)
RxNorm normalized name: tuberculin skin test; unspecified formulation
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabotegravir DT Formulation (test 1) will be administered.
Trial: NCT05776108
Drug: Cabotegravir DT Formulation (test 2)
RxNorm normalized name: tuberculin skin test; unspecified formulation
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabotegravir DT Formulation (test 2) will be administered.
Trial: NCT06317805
Drug: Generic treprostinil sodium + Standard of Care (Double Oral)
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Treprostinil (prostacyclin analogue) solution for continuous subcutaneous (SC) or intravenous (IV) infusion (1 mg/ml; 2.5 mg/ml; 5 mg/ml; 10 mg/ml in 10 mL glass vial) will be administered by an infusion pump system and up-titrated to ≥40 ng/kg/min or to the maximum tolerated dose within 24 weeks. Further up-titration shall be performed until trial completion according to the discretion of the investigator.
Trial: NCT06346561
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: the reduction of controlled hypotension and the control of hemodynamic responses of the body
Trial: NCT06346561
Drug: Labetalol
RxNorm normalized name: Labetalol
DrugBank: Labetalol (DB00598)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the reduction of controlled hypotension and the control of hemodynamic responses of the body
Trial: NCT06573593
Drug: Tofacitinib
RxNorm normalized name: Tofacitinib
DrugBank: Tofacitinib (DB08895)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In the real-world settings, patients with AA treated with tofacitinib.
Trial: NCT06573593
Drug: Baricitinib
RxNorm normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the real-world settings, patients with AA treated with Baricitinib.
Trial: NCT06573593
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In the real-world settings, patients with AA treated with Ruxolitinib.
Trial: NCT06573593
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the real-world settings, patients with AA treated with Upadacitinib.
Trial: NCT06573593
Drug: Abrocitinib
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the real-world settings, patients with AA treated with Abrocitinib.
Trial: NCT06573593
Drug: Ritlecitinib
RxNorm normalized name: Ritlecitinib
DrugBank: Ritlecitinib (DB14924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the real-world settings, patients with AA treated with Ritlecitinib.
Trial: NCT06531707
Drug: Loratadine
RxNorm normalized name: Loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suspension 1 mg / 1 mL, 5 mL twice a day
Trial: NCT04726982
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg once daily
Trial: NCT04726982
Drug: Acetazolamide
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg once daily
Trial: NCT06346977
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intrathecal injection of pemetrexed
Trial: NCT06391827
Drug: DA-7503 Multiple dose
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration once daily for 7 days; Dose strength or target volunteer is different for each cohort(Cohort 1,2,3, and 4)
Trial: NCT04988165
Drug: Traditional Chinese Medicine
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
DrugBank: Borneol (DB11288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a common prescription used in traditional Chinese medicine to treat diarrhea with remarkable efficacy.
Trial: NCT05160805
Drug: ONL1204 Ophthalmic solution (Dose B)
RxNorm normalized name: polymyxin B / trimethoprim Ophthalmic Solution [Polytrim]
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquid formulation administered by intravitreal (IVT) injection
Trial: NCT05647512
Drug: LM-305
RxNorm normalized name: LM-030
DrugBank: LM-030 (DB18283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT05647512
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT04823845
Drug: Topical Adapalene Gel 0.1%
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: applying Adapalene Gel 0.1% to plantar warts topically
Trial: NCT04825223
Drug: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine MenACYW conjugate vaccine
RxNorm normalized name: Neisseria meningitidis serogroup Y capsular polysaccharide tetanus toxoid protein conjugate vaccine
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Liquid solution for injection in a vial Route of administration: Intramuscular
Trial: NCT04689737
Drug: Doravirine
RxNorm normalized name: Doravirine
DrugBank: Doravirine (DB12301)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will be told to take one tablet of doravirine (Pifeltro, MDS) once daily, with or without food, approximately at the day time that they usually finish the hemodialysis sessions. The rest of their antiretroviral regimen and concomitant medications will remain unchanged
Trial: NCT06406205
Drug: Voclosporin（QL1074）
DrugBank: Voclosporin (DB11693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: QL1074 23.7 mg BlD will be administered as a fixed dose without the use of therapeutic drugmonitoring. The protocol contains provisions for management of dose based on safety concerns, in particular, BP and renal function，can be managed by dose reduction and temporary of QL1074 to interruption.
Trial: NCT06222476
Drug: Dorzagliatin
RxNorm normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzagliatin will be initiated and maintained at 75mg twice a day
Trial: NCT06222476
Drug: Gliclazide
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide will be initiated and maintained at 30mg once a day
Trial: NCT06142201
Drug: JT001
RxNorm normalized name: Apixaban
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral administration
Trial: NCT04989257
Drug: Ticagrelor-based dual-antiplatelet therapy
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin with ticagrelor
Trial: NCT04989257
Drug: Clopidogrel-based dual-antiplatelet therapy
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aspirin with clopidogrel
Trial: NCT06439758
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 1000 mg/day for 6 months
Trial: NCT06205290
Drug: Idelalisib
RxNorm normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT06205290
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06205290
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Specified dose on specified days
Trial: NCT06205290
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05264805
Drug: 0.25% Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20ml of 0.25% Bupivacaine subcutaneous infiltration at port site wound.
Trial: NCT05234346
Drug: 150 mg 5-ALAPhosphate + SFC
RxNorm normalized name: Isopropyl fluophosphate
DrugBank: Isoflurophate (DB00677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules in the morning after breakfast (before 11 AM) and 1 capsule in the evening after a snack or after dinner (before 8 PM) orally with water for 21 days.
Trial: NCT06293417
Drug: Ezetimibe/fenofibrate (Ezefeno) and moderate-intensity statin
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment group
Trial: NCT05768503
Drug: Control Rx
RxNorm normalized name: Control Rx
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The treatment option for the standard second-line FOLFIRI + bevacizumab therapy group is bevacizumab 5 mg/kg IV Drip Q2W, irinotecan 180 mg/m2 IV Drip Q2W, calcium folinate 400 mg/m2 IV Q2W or calcium levofolinate 200 mg/m2 IV Drip Q2W, 5-fluorouracil 400 mg/m2 IV +2400 mg/m2 CIV (infusion 46-48 hr) Q2W until loss of clinical benefit or development of intolerable toxicity (whichever occurs first), with a maximum treatment duration of 2 years.
Trial: NCT05249725
Drug: Irsogladine Maleate
RxNorm normalized name: maleate
DrugBank: Irsogladine (DB13056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administration of irsogladine maleate 4mg/day, for 8 weeks.
Trial: NCT05249725
Drug: Hydrotalcite
RxNorm normalized name: Hydrotalcite
DrugBank: Hydrotalcite (DB13322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were given 1 g hydrotalcite every morning, afternoon and evening for 8 weeks.
Trial: NCT06431620
Drug: Recombinant Human Thyroid Stimulating Hormone
RxNorm normalized name: Recombinant Human Thyroid Stimulating Hormone
DrugBank: Thyrotropin alfa (DB00024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: recombinant human thyrotropin (rhTSH) injection: 0.9mg/1.0mL/piece; intramuscular injection; once a day for two consecutive days.
Trial: NCT03938701
Drug: Adalimumab-800CW
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous administration of 4.5 mg, 15 mg or 25 mg 2 - 4 days prior to the fluorescence imaging
Trial: NCT06429306
Drug: Dexycu
RxNorm normalized name: Dexycu
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5ul dexamethasone, concentration: 103.4 μg/μl, equivalent to 517μg dexamethasone
Trial: NCT06572514
Drug: immunotherapy：pembrolizumab；chemo：albumin-bound paclitaxel and cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The immunotherapy drug was pembrolizumab at a dose of 200 mg, administered on the first day of each cycle every 3 weeks. The induction chemotherapy regimen included albumin-bound paclitaxel at 260 mg/m2 and cisplatin at 75 mg/m2, given every 3 weeks, either concurrently with immunotherapy or on the second day.
Trial: NCT04902105
Drug: ecopipam HCL
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Ecopipam (DB12273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets
Trial: NCT04902105
Drug: Divalproex Sodium ER
RxNorm normalized name: Divalproex Sodium ER
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral tablets
Trial: NCT06663254
Drug: Hydroxyethyl starch 130/0.4
RxNorm normalized name: Hydroxyethyl starch 130/0.4
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized goal-directed administration of 6% Hydroxyethyl starch (HES) 130/0.4: After the induction of anesthesia, 200 ml trial fluid will be infused over 20 min. If stroke volume (SV) increases \&gt;10%, another 200 ml fluid will be given. After that, the use of trial fluid will be determined by the patients' Stroke Volume Variation (SVV). If the SVV exceeds 12%, 200 ml trial fluid will be given over 20 min; this will be repeated until SVV \&lt;12%. If the use of HES exceeds 30 ml/kg, sodium acetate Ringer will be replaced. In addition, patients will have a background infusion of sodium acetate Ringer's solution at 4 ml/kg/h to satisfy the maintenance fluid requirements during surgery.